The suppressors of cytokine signaling (SOCS) are negative feedback inhibitors of cytokine signal transduction. SOCS3 is a key negative regulator of interleuking-6 (IL-6) signal transduction. Furthermore, SOCS3 was shown to be phosphorylated upon treatment of cells with IL-2, and this has been reported to regulate its function and half-life. We set out to investigate whether SOCS3 phosphorylation may play a role in IL-6 signaling. Tyrosine-phosphorylated SOCS3 was detected upon treatment of mouse embryonic fibroblasts with IL-6. Interestingly, the observed SOCS3 phosphorylation does not require SOCS3 recruitment to phosphotyrosine (Tyr(P)) 759 of gp130, and the kinetics of SOCS3 phosphorylation do not match the activation kinetics of the Janus kinases. This suggests that other kinases may be involved in SOCS3 phosphorylation. Using Src and Janus kinase inhibitors as well as Src kinase-deficient mouse embryonic fibroblasts, we provide evidence that Src kinases, which we found to be constitutively active in these cells, are involved in the phosphorylation of IL-6-induced SOCS3. In addition, we found that receptor-tyrosine kinases such as platelet-derived growth factor receptor or epidermal growth factor receptor can very potently phosphorylate IL-6-induced SOCS3. Taken together, these results suggest that SOCS3 phosphorylation is not a JAK-mediated phenomenon but is dependent on the activity of other kinases such as Src kinases or receptor-tyrosine kinases, which can either be constitutively active or activated by an additional stimulus.
Interleukin-6 (IL-6)
1 is a cytokine that plays important roles in the coordination and regulation of immune responses. It was first described as B-cell stimulating factor-2, which induces differentiation and proliferation of B and T cells (1) . Furthermore, IL-6 is the major mediator of acute phase proteins in rat hepatocytes (2) (3) (4) . It is also implicated in several immune diseases such as rheumatoid arthritis and multiple myeloma (5) .
IL-6-type cytokines transduce their signals via the JAK/ STAT and mitogen-activated protein kinase pathways (6, 7) . Their common signal-transducing receptor subunit, gp130, was shown to bind JAK1, JAK2, and TYK2 (8, 9) . Of these, JAK1 plays an essential role, because in cells lacking JAK1, IL-6 signal transduction is greatly impaired (10, 11) . Activation of the Janus kinases upon IL-6 stimulation induces receptor phosphorylation and subsequent recruitment of signaling proteins. Among these is STAT3, which binds to the four distal tyrosine motifs of gp130 (Tyr-767, Tyr-814, Tyr-905, and Tyr-915), becomes phosphorylated, and translocates to the nucleus to induce IL-6-responsive genes (12) (13) (14) (15) . Tyrosine 759 of gp130 has been suggested to be involved in the inhibition of IL-6 signaling since the mutation of this tyrosine to phenylalanine enhances IL-6 signaling (16, 17) . It was demonstrated that Tyr-759 can recruit both the tyrosine phosphatase SHP-2 and the feedback inhibitor suppressor of cytokine signaling 3 (SOCS3) (12, 16, 18, 19) . SHP-2 was shown to negatively regulate the IL-6 signaling pathway, but it was also reported that recruitment of SHP-2 to gp130 functions as an adaptor and leads to Ras/mitogen-activated protein kinase activation (20, 21) . SOCS3 belongs to the family of SOCS proteins that have been shown to be induced by a number of cytokines and growth factors (22) (23) (24) . The members of this protein family (CIS and SOCS1 to SOCS7) contain a central SH2 domain and a C-terminal SOCS box. SOCS3 is rapidly induced upon IL-6 stimulation and inhibits IL-6-mediated signaling in a classic feedback loop (18, 25) . The crucial role of SOCS3 for the inhibition of IL-6 signaling was recently confirmed in SOCS3-deficient macrophages (26 -28) . SOCS3 recruitment to the tyrosine motif Tyr-759 of gp130 was shown to be required for its inhibitory action (18, 19) . Several mechanisms by which SOCS proteins regulate cytokine signaling have been proposed; SOCS1, and to some extent SOCS3, were found to inhibit the kinase activity of JAKs by binding to the activation loop of the kinase (29, 30) . Another model for SOCS function proposes the targeting of signaling components to proteasome-dependent degradation (31) (32) (33) . SOCS proteins were shown to form an E3-ubiquitin ligase complex with elonginC, elonginB, cullin2/5, and ring box protein-1 (34) . It was reported that the C-terminal SOCS box of SOCS1 and SOCS3, which interacts with elonginC, is required for proteasomal degradation of SOCS binding partners such as TEL-JAK2, JAK2, Vav, and insulin receptor substrate-1 and -2 (35-39).
SOCS3 is tyrosine-phosphorylated upon IL-2, IL-3, erythropoietin (Epo), epidermal growth factor, platelet-derived growth factor, and insulin stimulation (40 -42) . This modification occurs on Tyr-204 and Tyr-221 within the SOCS box and seems to be involved in regulation of the stability of SOCS3 (41, 43) . Furthermore, it was reported that phosphorylated SOCS3 interacts with p120RasGAP to prolong extracellular signal-regulated kinase activation (41) .
The mechanism that underlies SOCS3 phosphorylation is not well understood. In previous studies it has been demonstrated that overexpression of Janus kinases or the Src kinase Lck leads to SOCS3 phosphorylation (40, 41, 43) . However, the kinase that triggers SOCS3 phosphorylation upon cytokine stimulation has not been identified so far.
We set out to investigate SOCS3 phosphorylation in the context of IL-6 signal transduction. We found IL-6-induced SOCS3 to be phosphorylated in MEF cells but that Janus kinases are not responsible for the observed phosphorylation. We provide evidence that IL-6-induced SOCS3 can be phosphorylated by other kinases such as Src kinases or receptor-tyrosine kinases (e.g. EGF receptor or PDGF receptor) in cells where these kinases are either constitutively active or have been activated by an additional stimulus.
EXPERIMENTAL PROCEDURES
Materials-The preparation of recombinant human IL-6 was performed by the method of Arcone et al. (44) . The soluble IL-6R␣ (sIL-6R␣) was prepared as previously described by Weiergrä ber et al. (45) . Recombinant human Epo was a generous gift from Drs. B. Hilger and K. H. Sellinger (Roche Applied Science). Murine OncostatinM (OSM) was obtained from R&D Systems, and human EGF and human PDGF-AB was purchased from Peprotech (London, UK). The gp130-derived peptides were described previously (18) and were kindly provided by Dr. J. Schneider-Mergener (Charité, Berlin, Germany). The proteasome inhibitor MG132 was obtained from Calbiochem, the Src kinase inhibitor PP1 was from Biomol (Hamburg, Germany), and the Janus kinase inhibitor 1 was from Calbiochem.
Plasmids-The plasmid pcDNA3-hSOCS3 was previously described (46) . pcDNA3-Myc-SOCS3 F25A and pCMV2-FLAG-SOCS3 were described previously (30) . Murine cDNAs encoding the glutathione Stransferase-tagged kinase domain of JAK2 (JAK2-JH1) and an inactive kinase domain where Tyr-1007 and Tyr-1008 are mutated to phenylalanine (JAK2-JH1FF) were kindly provided by Dr. A. Yoshimura (Kyushu University, Fukuoka, Japan). The N-terminal glutathione S-transferase tag was replaced by a yellow fluorescent protein (YFP) tag by transferring JAK2-JH1 into the previously described expression vector, pEF-JAK2-YFP (47) . pSVL-JAK1, pSVL-JAK2, pSVL-JAK3, and pSVL-TYK2 were described previously (48 -50) . pME18S-SOCS3-wt, pME18S-SOCS3-Y204F, pME18S-SOCS3-221F, and pME18S-SOCS3-FF were described previously (41) .
The preparation of cDNAs encoding different variants of the chimeric receptors EpoR/gp130 was described previously (15) . These constructs contain the extracellular part of the EpoR and the transmembrane and cytoplasmic parts of gp130. Chimeric receptor constructs EpoR/gp130 (YF4Y) and EpoR/gp130 (YY4F) contain tyrosine to phenylalanine substitutions within the cytoplasmic part of the receptor as indicated. The receptors were subcloned into the pM5 retroviral vector based on the myeloproliferative sarcoma virus containing the internal ribosome entry site (IRES) from the negative regulatory factor (NRF) followed by cDNA encoding a green fluorescent protein-Neo fusion protein.
Antibodies-For immunoprecipitations a SOCS3 rabbit antibody FA1017 (Fusion Antibodies, Belfast, UK), a SOCS3 rabbit polyclonal antibody C005 (IBL, Hamburg, Germany), and a JAK1-HR785 rabbit polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany) were used. For immunodetection, the following primary antibodies were used unless otherwise noted: SOCS3-M20 goat polyclonal antibody (Santa Cruz Biotechnology), JAK1-HR785 rabbit polyclonal antibodies JAK2-C20 and JAK3-C21 (Santa Cruz Biotechnology), TYK2-T20220 (BD Biosciences), Lck-FA1072 antibody (Fusion Antibodies), phosphotyrosine-specific STAT3 (pY705STAT3) rabbit polyclonal antibody (Cell Signaling, Frankfurt, Germany), STAT3 mouse antibody (BD Biosciences), green fluorescent protein mouse antibody (Santa Cruz Biotechnology), phosphotyrosine-specific Src (pY-418) rabbit polyclonal antibody, and a mixture of the phosphotyrosine mouse antibodies 4G10 (Upstate Biotechnology, Hamburg, Germany) and pY99 (Santa Cruz Biotechnology). Horseradish peroxidase-conjugated secondary antibodies were obtained from DAKO (Hamburg, Germany).
Cell Culture and Transfection-COS-7 cells, Yes/Fyn-deficient cells (Src ϩϩ ), Src/Yes/Fyn-deficient MEF cells (SYF), SYF cells reconstituted with c-Src (SYFϩc-Src), MEF cells, A431 (epidermoid cancer cell), and NIH-3T3 fibroblasts were purchased from ATCC. NIH-3T3 fibroblasts stably expressing wild type SOCS3 or mutant SOCS3 (SOCS3-FF) were described previously (41) . The cell lines were cultivated in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum (Seromed, Wien, Austria) and 1% penicillin/streptomycin (Invitrogen). Stable MEF cells were cultivated additionally in 1% neomycin (Sigma). COS-7 cells were transfected by the diethylaminoethyldextran method as described previously (49) . For stimulation, the cells were starved in medium without fetal calf serum and treated with 20 ng/ml IL-6 and 1 g/ml sIL-6R, 20 ng/ml OSM, 7 units/ml Epo, 50 ng/ml EGF, or 50 ng/ml PDGF-AB. The inhibitor MG132 was dissolved in Me 2 SO and used at a concentration of 10 M.
Retroviral Infection of Murine Embryonic Fibroblasts-Retroviral vectors pM5-EpoR/gp130 (6Y), pM5-EpoR/gp130 (YF4Y), and pM5-EpoR/gp130 (YY4F) were introduced into murine embryonic fibroblasts. Briefly, retroviral vectors were transfected together with Ecopack packaging vector and gag-pol vector into Hek293T cells, and after 48 h supernatants were collected and used in the presence of Polybrene (8 g/ml) for infection of target cells. After 48 h transduced cells were subjected for G418 selection. The expression of the chimeric receptors was verified using Western blotting. A pool of positive cells was used for the experiments.
Immunoprecipitation-For immunoprecipitation of endogenous proteins, about 3 ϫ 10 7 cells were lysed in 500 -800 l of lysis buffer (1% Triton X-100, 20 mM Tris/HCl (pH 7.6), 150 mM NaCl, 10 mM NaF supplemented with 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 5 g/ml aprotinin, 5 g/ml leupeptin, 5 g/ml pepstatin, and 10 M MG132) for 30 min at 4°C. Insoluble material was removed by centrifugation, and cell lysates were precleared with protein A-Sepharose (Amersham Biosciences) for 1 h at 4°C. After removal of the Sepharose, the lysates (1-3 mg of protein) were incubated overnight with specific antibodies at 4°C. The immune complexes were bound to protein ASepharose for 1 h at 4°C. After centrifugation the beads were washed 3 times with washing buffer (0.1% Triton X-100, 20 mM Tris/HCl (pH 7.6), 150 mM NaCl, 10 mM NaF, 1 mM Na 3 VO 4 ). The precipitated proteins were resolved by SDS-PAGE.
Peptide Precipitation Assay-COS-7 cells were transfected with pcDNA3-hSOCS3 (2 g) and pEF-YFP-JAK2-JH1 or pEF-YFP-JAK2-JH1 (3 g). Approximately 3 nM concentrations of biotinylated peptides were immobilized by incubation with 5 mg of NeutrAvidin-coupled Sepharose (Pierce) in 100 l of lysis buffer PP (150 mM NaCl, 50 mM Tris/HCl, 0.1 mM EDTA, 10% glycerin, 0.5% Nonidet P-40 (pH 8.0) per sample. For SOCS3 precipitation, transfected cells were lysed in lysis buffer PP supplemented with 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 5 g/ml aprotinin, 5 g/ml leupeptin, 5 g/ml pepstatin, and 10 M MG132, and the total cell lysates were incubated with the immobilized peptides at 4°C overnight. Precipitates were washed three times with lysis buffer PP. The precipitated proteins were resolved by SDS-PAGE.
Immunoblotting and Immunodetection-The electrophoretically separated proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Eschborn, Germany) by semidry Western-blotting method. Antigens were detected by incubation with specific primary antibodies and horseradish-peroxidase-coupled secondary antibodies (DAKO). The membranes were developed using the ECL detection system (Amersham Biosciences). Quantification of Western blot signals was performed using the Quantity one software (Bio-Rad).
RESULTS

SOCS3 Phosphorylation Is Observed upon Treatment of MEF
Cells with IL-6 or OSM-To investigate whether endogenous SOCS3 can be phosphorylated upon IL-6 stimulation, we treated 2fTGH, 2C4, HepG2, 293T, and MEF cells with IL-6. In 2fTGH, 2C4, HepG2, and 293T cells, IL-6 potently induces the expression of SOCS3 (data not shown). However, we found detectable SOCS3 phosphorylation to occur only in MEF cells treated with IL-6 (Fig. 1A) . Fig. 1A , upper panels, shows the kinetics of SOCS3 phosphorylation in MEF cells treated with IL-6 and sIL-6R. Because we found that phosphorylation of SOCS3 destabilizes the protein (43), the proteasome inhibitor MG132 was added to facilitate the detection of phosphorylated SOCS3 (pY-SOCS3). SOCS3 phosphorylation was seen after 60 min and persisted up to 180 min. The kinetics of phosphorylation exactly match those of SOCS3 protein expression. A control for which the cells were only treated with MG132 for 180 min (Fig. 1A, lane 7) shows that the inhibition of proteasomal degradation does not by itself lead to the accumulation of SOCS3 protein. To ascertain that the antibody FA1017 (Fusion Antibodies) precipitates the phosphorylated and non-phosphorylated forms of SOCS3 equally well, we compared this antibody with a SOCS3 antibody directed against the 18 N-terminal amino acids of SOCS3 (C005; IBL) (Fig. 1A , lower panels). As can be seen in Fig. 1A , lower panels; lanes 4 and 5, both antibodies FA1017 and C005 precipitate equal amounts of pY-SOCS3. The antibody C005 does not recognize the shorter SOCS3 isoform, which lacks the 11 N-terminal amino acids (51) .
We next checked whether SOCS3 phosphorylation could also be observed after stimulation of MEF cells with other IL-6-type cytokines. Because these cells express the OSM receptor on their cell surface, we compared IL-6 and OSM in their capacity to induce SOCS3 phosphorylation. As shown in Fig. 1B , pY-SOCS3 was also detected after treatment of MEF cells with OSM for 30 or 60 min.
The Kinetics of JAK Activation and SOCS3 Phosphorylation Do Not Match-It is well documented that SOCS3 is induced upon IL-6 stimulation via the JAK/STAT pathway and that the expression of this feedback inhibitor then leads to the inhibition of IL-6-mediated signaling (18, (25) (26) (27) (28) .
To compare the activation kinetics of IL-6 signaling components such as JAK1 and STAT3 with SOCS3 phosphorylation, MEF cells were stimulated with IL-6/sIL-6R, and SOCS3 was immunoprecipitated from the lysates (Fig. 2 ). SOCS3 expression was detectable at 30 and 60 as well as 120 min, and phosphorylation was visible at 60 and 120 min (Fig. 2 , upper two panels). Endogenous JAK1 was also immunoprecipitated, and its phosphorylation was monitored. Upon stimulation, JAK1 phosphorylation increased up to 30 min and then declined slowly until 120 min (Fig. 2, middle panels) . The increase in STAT3 phosphorylation parallels the JAK1 phosphorylation, but then Tyr(P)-STAT3 decreases much more dramatically and is hardly visible at 60 min (Fig. 2 , lower two panels). This decrease in STAT3 phosphorylation at 60 min correlated closely with the expression of the feedback inhibitor SOCS3. Thus, although JAK phosphorylation is still detectable at 60 and 120 min, the kinase is inhibited at this time. These results suggest that the Janus kinases may not be responsible for the observed SOCS3 phosphorylation.
Recruitment to gp130 Is Not Required for Phosphorylation of SOCS3 upon IL-6
Stimulation-IL-6-induced SOCS3 needs to be recruited to the tyrosine motif Tyr(P)-759 within the signal transducing receptor chain gp130 to exert its inhibitory action (18, 19) . Furthermore, it was shown that the Janus kinases are constitutively associated with this receptor chain (47, 52) . Thus, the question arises of whether SOCS3 recruitment to Tyr(P)-759 of gp130 is a prerequisite for SOCS3 phosphorylation.
To address this question MEFs were retrovirally transduced with chimeric receptors composed of the extracellular part of the EpoR and the transmembrane and intracellular regions of gp130. This system allows mechanistic studies with receptor mutants independent of endogenous gp130. Three different stable cell lines were generated in which the chimeric receptors differ in their cytoplasmic regions (Fig. 3A) . The cell line EpoR/ gp130 -6Y represents the wild type receptor in this system where all tyrosines in the intracellular part of gp130 are intact.
FIG. 1. SOCS3 tyrosine phosphorylation occurs upon treatment of MEF cells with IL-6 or OSM.
A, upper panels, MEF cells were stimulated with IL-6 (20 ng/ml) and sIL-6R (1 g/ml) for the indicated times in the presence of 10 M MG132. SOCS3 was immunoprecipitated (IP) and probed with a Tyr(P) (pY) and a SOCS3 antibody. Lower panels, MEF cells were stimulated with IL-6 and sIL-6R in the presence of the proteasome inhibitor MG132. SOCS3 was immunoprecipitated with the SOCS3 antibodies FA1017 (Fusion Antibodies) or C005 (IBL). Precipitates were probed with a Tyr(P) antibody, and SOCS3 counterstaining was performed with a SOCS3 antibody. WB, Western blot. B, MEF cells were stimulated with IL-6 (20 ng/ml) and sIL-6R (1 g/ml) or OSM (20 ng/ml) for the indicated times in the presence of MG132. After immunoprecipitation of SOCS3, the precipitates were detected with a Tyr(P) and a SOCS3 antibody.
FIG. 2. Activation kinetics of SOCS3, JAK1
, and STAT3 upon stimulation of MEF cells with IL-6. MEF cells were stimulated with IL-6 and sIL-6R for the times indicated in the presence of MG132. SOCS3 and JAK1 were immunoprecipitated (IP) from total cell lysates (TCL). Detection of SOCS3 was performed using a Tyr(P) (pY) and a SOCS3 antibody. JAK1 phosphorylation was detected by using Tyr(P) antibody mixture pY99/4G10, and counterstaining was performed with a JAK1-specific antibody. STAT3 protein and tyrosine phosphorylation was detected from total cell lysates using specific pY705STAT3 and STAT3 antibodies. WB, Western blot.
In the cell line EpoR/gp130-YF4Y, the tyrosine Tyr-759 of the SOCS3 recruiting motif VQYSTVVH is mutated to phenylalanine. The cell line EpoR/gp130-YY4F is a negative control where all STAT recruitment sites are mutated to avoid SOCS3 expression. Comparable expression levels of the different chimeric receptors in the three cell lines were confirmed by immunoprecipitation and Western blotting (data not shown).
After Epo stimulation of the different cell lines, endogenous SOCS3 was immunoprecipitated, and SOCS3 expression as well as SOCS3 phosphorylation was analyzed. Most interestingly, tyrosine phosphorylation was observed upon stimulation of both the wild type receptor as well as the mutant receptor (YF4Y), which cannot recruit SOCS3 (Fig. 3A, upper panels) . As a control, STAT3 activation was monitored. The stronger induction of SOCS3 upon stimulation of the chimeric receptor EpoR/gp130-YF4Y correlated with the expected stronger STAT3 activation observed in this cell line. This is due to the fact that neither SOCS3 nor the tyrosine phosphatase SHP-2, which has also been shown to inhibit IL-6 signaling via the Tyr-759 in gp130 (12, 20) , can bind to this receptor chimera (Fig. 3A, lower two panels) . As expected, no STAT3 activation and, thus, no SOCS3 expression was observed in the control cell line (YY4F), where all the STAT3 recruitment sites are mutated. These results show that SOCS3 phosphorylation upon IL-6 stimulation is independent of recruitment by gp130.
We took advantage of the EpoR/gp130-YF4Y cells, in which phosphorylation of SOCS3 is readily detectable, to investigate the effect of the proteasome inhibitor MG132 on the phosphorylation of SOCS3. For this the cells were treated with MG132 or were left untreated. Upon stimulation with Epo, phosphorylation of SOCS3 occurred both in MG132-treated and nontreated cells (Fig. 3B, left panels) . Interestingly, treatment with MG132 not only increased the total amount of SOCS3 but also increased the relative amount of pY-SOCS3 in the SOCS3 pool. To better evaluate this phenomenon we quantified the intensities of the Western blot bands (60-min time point) by densitometry. The bar diagram in Fig. 3B clearly shows that treatment with MG132 increases the portion of SOCS3 that is phosphorylated. This is in line with our previous observation that phosphorylation of SOCS3 affects its stability and reduces SOCS3 half-life (43) .
SOCS3 Phosphorylation Does Not Disrupt the Function of the SH2 Domain-Having found that SOCS3 phosphorylation appears to occur independently of receptor recruitment, we were interested in determining whether the phosphorylation of SOCS3 would on the other hand affects its ability to bind to gp130, which is dependent on the SOCS3 SH2 domain (20) .
To test this, a peptide precipitation assay was performed in which biotinylated peptides encompassing the tyrosine motif Tyr-759 of gp130 in a phosphorylated or non-phosphorylated form were used to precipitate SOCS3 and pY-SOCS3. To obtain the modified or non-modified form of SOCS3, it was coexpressed together with a YFP-tagged, constitutively active (JAK2-JH1) or inactive (JAK2-JH1FF) kinase domain of JAK2. (lanes 1-4) . SOCS3 analysis was performed as described above. The amount of phosphorylated SOCS3 versus total SOCS3 protein was compared by quantification of the 60-min time point (lanes 3 and 7) using the Quantity one software (bar diagram).
This hyperactive kinase domain is able to potently phosphorylate SOCS3 on Tyr-204 and Tyr-221 if it is overexpressed (43) . Fig. 4A shows that SOCS3 is efficiently phosphorylated upon overexpression of JAK2-JH1, whereas the inactive mutant JAK2-JH1FF is not able to induce SOCS3 phosphorylation (lanes 1 and 2) . Lanes 3 and 4 show controls lacking SOCS3 or JAK2-JH1, respectively. The lysates were then incubated with the phosphorylated or non-phosphorylated peptides. After peptide precipitation with NeutrAvidine-Sepharose, coprecipitation of phosphorylated and non-phosphorylated SOCS3 was monitored using a phosphotyrosine-and a SOCS3-specific antibody. Fig. 4B demonstrates that both phosphorylated and non-phosphorylated SOCS3 bound to the phosphorylated peptide Tyr(P)-759 (lanes 1 and 2) . As expected, the control lanes with a non-phosphorylated Tyr-759 peptide (lanes 5-8) did not show significant SOCS3 binding. Thus, tyrosine phosphorylation of SOCS3 does not disrupt the function of the SH2 domain.
SOCS3 Phosphorylation Observed upon IL-6 Stimulation Can Be Blocked by the Src Kinase Inhibitor PP1-Because
SOCS3 phosphorylation was first shown to occur upon treatment of cells with IL-2 (40), a cytokine known to activate the Src kinase Lck, we investigated whether Src kinases could be responsible for the observed SOCS3 phosphorylation in MEF cells. For this we stimulated MEF cells stably expressing EpoR/gp130-YF4Y with Epo in the presence of increasing amounts of the Src kinase inhibitor PP1 and the Janus kinase inhibitor JAK inhibitor 1. SOCS3 was precipitated from the lysates and subjected to Western blot analysis (Fig. 5,  upper two panels) . As a control, STAT3 phosphorylation was also monitored (Fig. 5, lower two panels) . We found SOCS3 phosphorylation to be dramatically decreased upon treatment of the cells with the Src kinase inhibitor PP1 at concentrations of 5, 10, and 20 M (Fig. 5, lanes 3-6) . STAT3 activation was not affected, showing that the inhibitor did not block the JAK/STAT pathway. Treatment with PP1 at a concentration of 1 M already potently inhibited SOCS3 phosphorylation (data not shown). In sharp contrast, the JAK inhibitor 1 did not affect SOCS3 phosphorylation at concentrations of 50, 100, and 150 nM, whereas STAT3 phosphorylation was dose-dependently reduced (lanes 3, 7, 8, and 9 ). Higher concentrations of this inhibitor were usually avoided to prevent nonspecific effects. Taken together, these findings indicate that SOCS3 phosphorylation may primarily be mediated by kinases of the Src family.
The Src Kinase Lck Potently Phosphorylates SOCS3-The isolated kinase domain of JAK2 (JAK2-JH1) is able to potently phosphorylate SOCS3 if both proteins are cotransfected in COS-7 cells (Ref. 43 and Fig. 4) . It is known that the activity of the isolated kinase domain of JAK2 is about 50-fold increased if compared with the kinase domain within the full-length protein (53) . We next checked whether the JAK2-JH1-mediated SOCS3 phosphorylation could be dependent on Src kinases. COS-7 cells were cotransfected with expression vectors that encode SOCS3 and JAK2-JH1. After 48 h the cells were incubated with increasing amounts of PP1 inhibitor. Fig. 6A shows that the JAK2-JH1-induced SOCS3 phosphorylation is not affected by the Src kinase inhibitor PP1, suggesting that FIG. 5. SOCS3 phosphorylation upon IL-6 stimulation is inhibited by the Src kinase inhibitor PP1. MEF cells, which stably express the chimeric receptor EpoR/gp130-YF4Y, were stimulated with Epo for the indicated times in the presence of MG132. Cells stimulated for 120 min were then incubated with increasing amounts of PP1 or JAK Inhibitor 1. SOCS3 was immunoprecipitated (IP) from lysates, and SOCS3 phosphorylation was detected with a Tyr(P) (pY)-specific antibody. SOCS3 counterstaining was performed using a SOCS3 antibody. STAT3 activation was detected from lysates with specific pY705STAT3 and STAT3 antibodies. WB, Western blot; TCL, total cell lysate.
FIG. 4. SOCS3 phosphorylation does not abrogate the function of the SOCS3 SH2 domain. A, COS-7 cells
were transiently cotransfected with expression vectors coding for SOCS3 (pcDNA3-hSOCS3, 2 g) and YFP-tagged active JAK2-JH1wt (WT) or inactive JAK2-JH1FF (FF) (3 g), respectively. The cells were incubated with MG132 for 4 h before lysis. Phosphorylation of SOCS3 and JAK2-JH1wt was detected from total cell lysates (TCL) using a mixture of phosphotyrosine-specific antibodies (pY99/4G10). Counterstaining for SOCS3 and the YFP-JAK2 constructs was performed using a SOCS3 or a YFP-specific antibody. pY, Tyr(P); WB, Western blot. B, peptide precipitation assay using a phosphorylated or non-phosphorylated peptide. The biotinylated peptides Tyr(P)-759 and Tyr-759 were incubated with COS-7 lysates and were then precipitated with NeutrAvidine-Sepharose. The precipitates were resolved by SDS-PAGE, and SOCS3 coprecipitation was investigated using a Tyr(P) and a SOCS3-specific antibody.
the highly active JAK2-JH1 is able to directly phosphorylate SOCS3 upon overexpression.
In previous studies it was also shown that overexpression of full-length JAK1 can induce SOCS3 phosphorylation (40, 41, 43) . To compare the potency of full-length JAK1 and Lck to phosphorylate SOCS3, we cotransfected SOCS3 with either Lck or JAK1 expression vectors (Fig. 6B) . After 48 h the constitutive activity of the kinases was blocked by treatment of the cells with increasing amounts of JAK inhibitor 1 or PP1. Overexpression of JAK1 leads to the constitutive activation of STAT3 (Fig. 6B, lane 2) . This activation can be blocked by the JAK inhibitor 1 (lanes 5 and 6) but not by the Src kinase inhibitor PP1 (lane 3 and 4) . Although JAK1, at these expression levels, was able to potently phosphorylate STAT3, SOCS3 tyrosine phosphorylation could not be observed (upper panel,  lanes 2-6) . In contrast, very strong SOCS3 phosphorylation FIG. 6 . The Src kinase Lck potently phosphorylates SOCS3. A, COS-7 cells were cotransfected with expression vectors encoding for SOCS3 (pCMV2-FLAG-SOCS3, 2 g) and YFP-JAK2-JH1 (3 g) or with empty vector. Cells were incubated with MG132 for 4 h, and increasing amounts of PP1 were added for 1 h. The detections were carried out using total cell lysates. SOCS3 phosphorylation and SOCS3 protein were detected from the lysates using a specific Tyr(P) (pY) and a SOCS3 antibody. JAK2-JH1 activation was detected using an antibody that specifically detects the phosphorylated tyrosines 1007 and 1008 in the activation loop of the kinase (JAK2-JH1pYpY). JAK2-JH1 counterstaining was performed using a YFP-antibody. WB, Western blot; TCL, total cell lysates; GFP, green fluorescent protein. B, COS-7 cells were transfected with expression vectors encoding for SOCS3 (pCMV2-FLAG-SOCS3, 0.5 g) and JAK1 or Lck (3 g). Cells were incubated with MG132 for 4 h and treated with increasing amounts of PP1 and JAK inhibitor (Inh) 1 for 1 h. pY-SOCS3, SOCS3, phosphorylated STAT3, JAK1, and Lck were detected from total cell lysates using specific antibodies recognizing Tyr(P), SOCS3, pY705STAT3, JAK1, and Lck. C, COS-7 cells were cotransfected with an expression vector encoding for SOCS3 (pCMV2-FLAG-SOCS3, 1 g) and increasing amounts of an expression vector encoding for Jak1 as indicated. Cells were incubated with MG132 for 4 h before lysis. Phosphorylated Jak1 and SOCS3 were detected using a Tyr(P) antibody. SOCS3 and Jak1 were detected with specific antibodies recognizing SOCS3 and Jak1. D, COS-7 cells were transfected with expression vectors coding for JAK1, JAK2, JAK3, TYK2, or Lck (3 g) together with the SOCS3-F25A mutant (0.5 g). Phosphorylation of SOCS3 was checked with a Tyr(P) and a SOCS3 antibody. Phosphorylation of the kinases was assessed with a Tyr(P) antibody, and their expression was monitored using antibodies against JAK1, JAK2, JAK3, TYK2, and Lck. E, COS-7 cells were transfected with expression vectors coding for SOCS3-wt, SOCS3-Y204F, SOCS3-Y221F, and SOCS3-FF (1 g) together with Lck (1 g). Phosphorylation and expression of SOCS3 and Lck was checked with a Tyr(P), a SOCS3 (C005), and an Lck antibody.
was detected upon overexpression of Lck (lane 7), which was inhibited by PP1 (lanes 8 and 9) but not by the JAK inhibitor 1 (lane 10 and 11). The fact that the JAK inhibitor 1 does not influence SOCS3 phosphorylation indicates that Lck may phosphorylate SOCS3 directly. The absence of pY-SOCS3 in cells expressing JAK1 at levels sufficient to induce a constitutive STAT3 phosphorylation supports the idea that Janus kinases do not contribute to SOCS3 phosphorylation under physiological conditions, although they may do so if sufficiently overexpressed. To check this hypothesis, we coexpressed SOCS3 with increasing amounts of JAK1 (Fig. 6C) . Fig. 6C shows that although JAK1 autophosphorylation is easily detectable at the lowest JAK1 expression level (lane 2), SOCS3 phosphorylation is only visible at the highest JAK1 expression level (lane 6). This finding confirms our previous observation that JAK1 overexpression can lead to SOCS3 phosphorylation (40, 41, 43) but further suggests that JAK1 is not the kinase that phosphorylates SOCS3 under physiological conditions.
We next investigated the potency of the different Janus kinase family members to phosphorylate SOCS3 upon overexpression of the kinases. To avoid partial inhibition of the Janus kinases by SOCS3, we cotransfected a SOCS3 construct carrying a mutation in the kinase inhibitory region (SOCS3-F25A) together with the different kinases. It was previously shown that this mutation disrupts the inhibitory function of SOCS3 (30) . Although the expression levels of the different kinases cannot be compared directly, Fig. 6D shows that JAK levels that are sufficient to induce autophosphorylation do not necessarily lead to SOCS3 phosphorylation. In cells transfected with Lck, SOCS3-F25A was well phosphorylated. Interestingly, cotransfection of JAK3 reduced SOCS3 expression levels. The underlying mechanism is currently unclear.
Because the tyrosine residues Tyr-204 and Tyr-221 in SOCS3 were shown to be phosphorylated upon IL-2 stimulation as well as upon overexpression of JAK1 or the isolated JAK2-JH1 domain (41, 43) we asked whether Lck would also lead to the phosphorylation of these two tyrosine residues. COS-7 cells were cotransfected with Lck and different SOCS3 constructs encoding for wt-SOCS3, SOCS3-Y204F, SOCS3-Tyr-221F, or the double mutant SOCS3-FF. Fig. 6E shows that Lck phosphorylates both Tyr-204 and Tyr-221 (lanes 4 and 5) . Tyrosine Tyr-204 is more prominently phosphorylated than tyrosine Tyr-221. The double mutant SOCS3-FF, where both tyrosines Tyr-204 and Tyr-221 are mutated to phenylalanine, is not phosphorylated (lane 6).
SOCS3 Phosphorylation upon IL-6 Stimulation Is Impaired in Src Kinase-deficient MEF Cells-To further explore the hypothesis that Src kinases may be involved in the phosphorylation of SOCS3, we took advantage of Src-deficient MEF cells (called SYF cells) that lack all three Src kinase family members (Src, Yes, and Fyn) expressed in wild type MEF cells. As a control we used MEF cells in which only Yes and Fyn were depleted but that still express Src (Src ϩϩ cells) and SYF cells which have been reconstituted with c-Src (SYFϩc-Src cells) (54) . First, SYF and Src ϩϩ cells were stimulated with IL-6 for 30 or 90 min, and SOCS3 induction and phosphorylation was analyzed. Fig. 7A , upper panel, shows that SOCS3 protein expression is detectable after 90 min in both cell lines, but that SOCS3 phosphorylation is only prominent in Src ϩϩ cells, although a residual amount of pY-SOCS3 seems to remain in SYF cells (Fig. 7A, upper two panels) . To better evaluate the decrease in SOCS3 phosphorylation, we quantified the intensities of the Western blot bands (90-min time point) by densitometry. The bar diagram in Fig. 7A shows that the relative amount of phosphorylated SOCS3 is decreased about 6-fold in SYF cells compared with Src ϩϩ cells. To check whether the reconstitution of c-Src would restore SOCS3 phosphorylation in IL-6-stimulated cells, SYF cells were compared with SYFϩc-Src cells in their ability to phosphorylate IL-6-induced SOCS3. Fig. 7B , upper panels, shows that despite a reduced SOCS3 expression, the reconstituted cells (SYFϩc-Src) show an increased phosphorylation of IL-6-induced SOCS3 if compared with SYF cells. A densitometric analysis of the 90-min time point (Fig. 7B, bar diagram) shows that the relative amount of phosphorylated SOCS3 is increased about 4-fold in the reconstituted cells in comparison to SYF cells. However, a residual SOCS3 phosphorylation was again detected in the SYF cells. As a control, the lysates from the same experiments were checked for the activation of Src kinases as well as STAT3. The detection with a phosphospecific antibody recognizing activated Src kinases shows that Src is constitutively active in Src ϩϩ cells and SYFϩc-Src (Fig. 7, A and B, total cell lysates (TCL), middle panel). STAT3 activation is comparable in all three cell types (Fig. 7, A and B, TCL, lower two panels) .
SOCS3 phosphorylation upon IL-6 stimulation of MEF cells, thus, seems to occur constitutively in a Src kinase-dependent manner. However, our findings show that Src kinases are not solely responsible for the constitutive phosphorylation of IL-6-induced SOCS3 and that other kinases also contribute to this phosphorylation.
EGF as Well as PDGF Induce Strong Phosphorylation of IL-6-induced SOCS3-Because we found that Src kinases are not exclusively responsible for the constitutive phosphorylation of IL-6-induced SOCS3 (Fig. 7) , we investigated whether other kinases could also efficiently phosphorylate SOCS3 in a cross-talk event. It has been reported that stimulation of cells with EGF or PDGF induces SOCS3 expression and phosphorylation (41) . But the induction of SOCS3 upon RTK activation (e.g. PDGF receptor) is generally much lower than cytokine-mediated SOCS3 expression. This correlates with their weaker ability to activate STAT factors (Fig. 8A) . Because IL-6 induces SOCS3 very potently and because our results show that SOCS3 phosphorylation is not an IL-6-mediated event, we were interested in investigating whether RTKs are also able to efficiently phosphorylate IL-6-induced SOCS3. We prestimulated A431 cells for the indicated times (0, 20, and 60 min) with IL-6 and subsequently treated the cells with EGF for 15 min before they were harvested. Fig. 8B shows that IL-6-induced SOCS3 (60-min stimulation with IL-6, lane 6) is strongly phosphorylated by the short EGF pulse. The same was observed when NIH-3T3 fibroblasts were prestimulated with IL-6 and then treated with PDGF for 15 min. Although IL-6 stimulation alone only leads to a weak phosphorylation of SOCS3 (lanes 5 in Fig. 8B ), which is probably due to some basal kinase activity in these cells (as we observed in MEF cells), an additional short stimulation with EGF or PDGF results in a strong phosphorylation of the IL-6-induced SOCS3.
Because RTKs such as PDGF receptor were shown to activate Src kinases (55) we next investigated whether the PDGFmediated phosphorylation of IL-6-induced SOCS3 is Src kinasedependent. For this, MEF and SYF cells were first stimulated with IL-6 for 90 min to induce SOCS3. Then the cells were treated with PDGF for 15 min to phosphorylate SOCS3. As we observed before (Fig. 7) , the weak constitutive phosphorylation of SOCS3 detected in MEF cells upon IL-6 stimulation (Fig. 8C,  lane 2) is strongly reduced in the SYF cells (lane 5), arguing that Src kinases are involved in this process. However, Fig. 8C clearly shows that PDGF potently phosphorylates the IL-6-induced SOCS3 both in MEF cells and in the Src kinasedeficient SYF cells (Fig. 8C, lanes 3 and 6) , demonstrating that Src kinases are not required for PDGF mediated SOCS3 phosphorylation. This shows that in addition to Src kinases, other tyrosine kinases can phosphorylate IL-6-induced SOCS3.
To further assess the extent of SOCS3 phosphorylation upon stimulation of cells with IL-6 or PDGF, we treated NIH-3T3 cells stably expressing wild type SOCS3 (SOCS3-wt) or mutant SOCS3 (SOCS3-FF) with IL-6 or PDGF. As shown in Fig. 8D , SOCS3 can be constitutively phosphorylated in SOCS3-wt-expressing cells (lane 1) and does not increase upon stimulation with IL-6 (lanes 2-4). Upon treatment with PDGF ( lanes 5-7) , a clear increase in SOCS3 phosphorylation is observed. In contrast, both the constitutive as well as the PDGF-induced phosphorylation of SOCS3 is lost in cells expressing the double tyrosine mutant SOCS3-FF. Together with the data presented before, this suggests that SOCS3 phosphorylation is not relevant in JAK-mediated IL-6 signaling but may become relevant during cross-talk events involving constitutively active kinases or simultaneous treatment of cells with growth factors such as PDGF or EGF.
DISCUSSION
SOCS3 was shown to be a key negative regulator of IL-6 signal transduction (18, (25) (26) (27) (28) . It is tyrosine-phosphorylated on two tyrosine residues within the C-terminal SOCS box upon stimulation with cytokines and growth factors such as IL-2, IL-3, Epo, EGF, and PDGF (40, 41) . The mechanism that underlies this phosphorylation is not well understood. In previous studies it has been demonstrated that overexpression of Janus kinases or the Src kinase Lck can lead to SOCS3 phosphorylation. However, the kinase that triggers SOCS3 phosphorylation under physiological conditions has not been identified so far.
We set out to investigate whether SOCS3 phosphorylation may play a role in IL-6 signaling. Tyrosine-phosphorylated SOCS3 was detected upon treatment of MEFs with IL-6 and OSM (Fig. 1) . Further studies showed that the observed phosphorylation did not require SOCS3 recruitment to the receptor and that the kinetics of SOCS3 phosphorylation did not match the activation kinetics of the Janus kinases (Figs. 2 and 3) . These results indicated that Janus kinases may not play a role in physiological SOCS3 phosphorylation.
Because IL-2, the first cytokine for which SOCS3 phosphorylation was reported, activates both Janus kinases and the Src kinase family member Lck (56, 57), we checked whether Src kinases could mediate SOCS3 phosphorylation. Using inhibitors, we found that a Src kinase but not a Janus kinase inhibitor was able to suppress the phosphorylation of IL-6-induced SOCS3 (Fig. 5) .
Because Janus kinases were found to phosphorylate SOCS3 Precipitates were blotted and detected with a Tyr(P) (pY) and a SOCS3 antibody. Activated Src kinase and phosphorylated STAT3 were detected from total cell lysates (TCL) from the same experiment using the phosphospecific antibodies pY418Src and pY705STAT3. To check for equal protein amounts in the samples, a STAT3 counterstaining was performed using a STAT3-specific antibody. The amount of phosphorylated SOCS3 in the different cell lines was compared by quantification of the 90-min time point using the Quantity one software (bar diagram). The values for pY-SOCS3 were normalized to SOCS3 expression, and the value obtained in SYF cells was set to 1. WB, Western blot.
upon overexpression (40, 41, 43) , we cotransfected SOCS3 with different Janus kinases or Lck. Lck potently phosphorylated SOCS3, whereas cotransfection of JAKs did not show prominent SOCS3 phosphorylation. Fig. 6 indicates that only highly overexpressed Janus kinases lead to a detectable SOCS3 phosphorylation. To back up the studies involving kinase inhibitors, we took advantage of Src kinase-deficient MEF cells (Fig. 7) . In the cell line (Src ϩϩ ) lacking two of the three Src kinases expressed in MEF cells, namely Yes and Fyn, and in a Srcdeficient cell line in which c-Src has been reconstituted (SYFϩc-Src) SOCS3 phosphorylation could be detected after the induction of SOCS3 by IL-6. In contrast, SOCS3 phosphorylation was reduced in SYF cells, whereas Src, Yes, and Fyn are depleted. This confirms that Src kinases are involved in the phosphorylation of SOCS3 in MEF cells stimulated with IL-6. We detected a constitutive Src kinase activation in these cells that was not increased upon treatment with IL-6 (Fig. 7) . This is in line with a previous report which shows that Src is constitutively active in Src ϩϩ cells (54) . Our results suggest that the observed phosphorylation of SOCS3 in MEF cells is not an IL-6-mediated phenomenon but is rather due to cross-talk events involving constitutively active Src kinases. The residual SOCS3 phosphorylation remaining in SYF cells indicates that other kinases may also be able to contribute to SOCS3 phosphorylation. For example, a short stimulation with EGF and PDGF leads to a strong phosphorylation of IL-6-induced SOCS3 in A431 and NIH-3T3 cells, respectively (Fig. 8B) . Using the Src kinase-deficient cells we could further show that the PDGF-mediated phosphorylation of IL6-induced SOCS3 is Src kinase-independent (Fig. 8C) .
Taken together, the observations indicate that even though the IL-6-driven JAK/STAT pathway strongly induces SOCS3, it does not mediate its phosphorylation. Rather, SOCS3 is phosphorylated by constitutively active kinases, such as Src kinases in MEF cells or by another extracellular stimulus, such as EGF and PDGF. In this case, SOCS3 phosphorylation may, thus, become relevant during cross-talk events.
Src kinases and RTKs have been implicated in the development of numerous human cancers and are constitutively active in many cells. c-Src for example has been found to be highly activated in colon cancers, especially in metastatic liver cancers (58, 59). Furthermore, in multiple myeloma cells, IL-6 was FIG. 8. IL-6-induced SOCS3 is strongly phosphorylated upon stimulation with RTKs. A, NIH-3T3 fibroblasts were stimulated with IL-6/sIL-6R or PDGF for the indicated times. SOCS3 immunoprecipitation (IP) was performed with a SOCS3 antibody. Precipitates were blotted (WB) and detected with SOCS3 antibody. STAT3 activation was detected from total cell lysates (TCL) using the phosphospecific antibody pY705STAT3 and a STAT3 antibody. B, human epidermoid cancer cells (A431) and NIH-3T3 fibroblasts were prestimulated for the indicated times with IL-6 alone or with IL-6/sIL-6R in the presence of MG132. Subsequently, a 15-min stimulation with 50 ng/ml EGF (A431) or 50 ng/ml PDGF-AB (NIH-3T3) was performed. IL-6-induced SOCS3 was immunoprecipitated with a SOCS3 antibody. Precipitates were blotted and detected with a Tyr(P) (pY) and a SOCS3 antibody. C, MEF and SYF cells were treated with MG132 and then prestimulated with IL-6 and sIL-6R for 90 min or were left untreated. Subsequently, a second stimulation with PDGF-AB (15 min) was performed. SOCS3 was immunoprecipitated using a SOCS3 antibody. Precipitates were blotted, and detection was done with a Tyr(P) and a SOCS3 antibody. D, 3T3 cells stably expressing SOCS3-wt or SOCS3-FF were stimulated with IL-6 and sIL-6R or PDGF-AB for the indicated times. SOCS3 was immunoprecipitated with a SOCS3 antibody, and detection was performed using a Tyr(P) and a SOCS3 antibody.
reported to activate the Src kinase Hck, which was proposed to mediate the proliferative effects of gp130 (60) . Because IL-6 is the most important growth factor involved in the proliferation of multiple myeloma cells, it would be interesting to determine whether SOCS3 phosphorylation contributes to malignant growth. Our finding that constitutive activation of Src kinases and the activation of RTKs lead to the phosphorylation of SOCS3 protein induced by cytokines (e.g. indicates that phosphorylation of SOCS3 may contribute to the oncogenic potential of these kinases. This could be achieved via several mechanisms. Because phosphorylated SOCS3 was reported to inhibit the Ras inhibitor p120RasGAP (41), one possible mechanism could be a prolonged extracellular signal-regulated kinase activation leading to increased proliferation of the cancer cells. Furthermore, SOCS3 stability as well as its interaction with the E3-ubiquitin ligase component elonginC was shown to be reduced upon phosphorylation of SOCS3 (43) . This may impair the postulated E3-ubiquitin ligase function of SOCS3 and, thus, the degradation of proteins interacting with SOCS3. For example, a similar mechanism is involved in the development of the von Hippel-Lindau syndrome. The von HippelLindau tumor suppressor protein, which is also part of an E3-ubiquitin ligase complex containing elonginB, elonginC, cullin2, and ring box protein-1, interacts with elonginC via its SOCS box (61) (62) (63) . Formation of this complex stabilizes the von Hippel-Lindau protein, and mutations in the SOCS box disrupting the interaction with elonginC were shown to abolish its E3-ubiquitin ligase function, leading to impaired degradation of recruited hypoxia inducible factor-1␣ (64, 65) . Such mutations were found in patients with dominant inherited von Hippel-Lindau syndrome, characterized by the predisposition to develop various benign and malignant tumors (66, 67) . In a very recent publication, a similar mechanism was also postulated for the E3-ubiquitin ligase function of SOCS1 (68) . The authors reported that v-Abl-induced modifications of SOCS1 disrupt its binding to elonginC and may, thus, impair SOCS1-dependent degradation of Janus kinases. In addition, pY-SOCS3 may also contribute to disease via another mechanism. Because phosphorylation of SOCS3 decreases its half-life, the levels of SOCS3 induced upon stimulation with cytokines such as IL-6 could be reduced in cancer cells where Src kinases or RTKs are highly activated. This could lead to enhanced and prolonged cytokine signals and contribute to the malignant transformation of cells. This paper strongly indicates that cytokine-driven JAK activation is not involved in the physiological phosphorylation of SOCS3. Phosphorylation of SOCS3 seems to be more relevant during cross-talk events in which cytokines induce high levels of SOCS3 protein that in turn is then strongly phosphorylated in response to other extracellular stimuli or via constitutively active kinases. Our data clearly suggest that such a cross-talk leads to much higher cellular levels of phosphorylated SOCS3 than a single cytokine or growth factor stimulus. The effects of this high SOCS3 phosphorylation on the different signaling pathways involved in such a cross-talk event (e.g. IL-6-and RTK-induced signaling pathways) remain unclear and are currently under investigation.
